hc1 Insights

hc1 is a growth-stage operating company, not an investment firm — it does not deploy capital into portfolio companies or manage third-party funds. The firm provides an AI-powered lab intelligence platform to health systems. Bradley Bostic is Chairman and CEO, and strategic decisions are made by the leadership team listed on the company's website.

hc1 IQ connects to laboratory information systems, electronic health records, and supply chain platforms through APIs, without requiring a rip-and-replace of existing infrastructure. The firm's stated design principle is to overlay its agentic intelligence onto data the lab already generates, processing that data continuously to surface prioritized alerts and workflow recommendations.

hc1 operates as a standalone enterprise selling software and advisory services to healthcare organizations. It is not a family office and, based on publicly available information, does not appear to manage a fund of outside capital. The firm's revenue comes from licensing its hc1 IQ platform and delivering consulting engagements to health systems.

The firm's website references average annual savings exceeding $1.2 million per health system, a 20% reduction in unnecessary testing, and a 40% faster time to clinical intervention. It also touts a case study in which a regional health system identified over $1.2 million in unnecessary testing within 90 days of deployment. The 94% turnaround time performance metric is cited as an operational benchmark in active accounts.

The hc1 IQ platform consists of four modules. Clinical IQ identifies at-risk patients and care gaps. Ops IQ provides real-time visibility into lab turnaround times and workflow bottlenecks. Source IQ benchmarks supply contracts and forecasts reagent needs. Signal IQ analyzes market share, referral patterns, and client churn risk for lab outreach teams.

In 2023, hc1 acquired Accumen, a consulting firm focused on lab performance optimization. The deal added deep consulting expertise that complements the software platform, allowing hc1 to offer health systems an integrated combination of technology and advisory services for lab transformation. The firm described the acquisition as completing an end-to-end partner for lab performance.

hc1's positioning emphasizes laboratory data as a central organizing layer for health system intelligence, deliberately distinct from broader analytics platforms built primarily on claims or EHR data. The firm does not market its product as a general-purpose healthcare analytics tool, and its language focuses on activating the diagnostic and operational signals specific to the lab domain.